did the fda stop semaglutide 🚨 Moves to Shut Down Mass-Market Compounded GLP-1s FDA is taking action to restrict widely marketed, non–FDA-approved compounded GLP-1 products, citing concerns over safety, quality, and misleading claims. As demand US FDA warns online vendors

Always follow the angle specified in your device IFU or by your trial team

The transparency around what the medication can and cannot do for a patient is the weakest piece of the entire safety pillar, and we graded it a zero for this category

Actual weight lost is dependent on a number of factors but many clients lose around 5% of their initial body weight

!

In the T2D groups, 3.6% of those with semaglutide and 5.4% of those with DPP4i as index treatment initiated insulin during follow-up

This information can support a more personalized conversation about whether GLP-1 agonist therapy, dual-receptor compounds, or alternative approaches align with your metabolic needs